Page 2504 - Williams Hematology ( PDFDrive )

2475
2474 Index Index 2475

multipotential cell therapy for, 452–453 laboratory features, 575–576, 575f, 575t, PCH (paroxysmal cold hemoglobinuria),
primary lymphoma, 1581 576t, 577f, 577t 837, 839, 2348
Pancytopenia pregnancy and, 580 PCI (percutaneous coronary intervention),
in acute lymphoblastic leukemia, 1514 prognosis, 581 2295
in clonal myeloid disorders, 1277 screening recommendations, 575t PCMZL (primary cutaneous marginal zone
consultative approach to, 43 therapy B-cell lymphoma), 184t, 1581
differential diagnosis, 1513 eculizumab, 578 PCP (pentachlorophenol), 517
in hairy cell leukemia, 1555 hematopoietic cell transplantation, PC-TP, 1853
in HIV infection, 1253t 579–580, 579t pCyR (partial cytogenic response), 1452t
with hyperplastic marrow, 1342 supportive, 578–579 PD-1 (programmed death-1), 424, 1755
Panobinostat, 240, 1754 thrombophilia management, 580 PD-1 (programmed death-1) receptor, 416
Pantothenate kinase-associated PARs (proteinase-activated receptors), 290. PDCD1 (CD279), 1184
neurodegeneration (PKAN), 682 See also Protease (proteinase)- PDGF (platelet-derived growth factor), 1322,
Pantothenic acid deficiency, 652 activated receptor (PAR)-1 1845, 1848
Papaverine, cAMP inhibition and, 404 Partial cytogenic response (pCyR), 1452t PDGFR-α, 1279, 1468t
Papillon-Lefèvre syndrome, 1013 Particle film, 29 PDGFR-β (PDGFRB), 232t, 1468, 1469
Pappenheimer bodies, 468, 868, 869 Parturition, iron deficiency in, 630 PDW (platelet volume distribution width), 17
PAR. See Protease (proteinase)-activated Parvovirus B19 infection PEAR1, 1853
receptor (PAR)-1 antiphospholipid antibodies and, 2234 Pearson marrow-pancreas syndrome, 919,
Paracentric inversion, 175t aplastic crisis and, 767 920
Paragangliomas, 560, 872, 878–879 erythema and, 2104, 2105f PECAM-1. See Platelet-endothelial cell
Parahemophilia (factor V deficiency). See hereditary spherocytosis and, 674 adhesion molecule-1 (PECAM-1,
Factor V deficiency immunoglobulins for, 544–545, 545f CD31)
Paranasal sinuses, primary lymphomas in, persistent, red cell aplasia and, 543, 544– PEG (monomethoxypolyethylene glycol), 332
1581 545, 545f, 1251–1252, 1542 Pegaspargase, 1515
Paraneoplastic vasculitis, 2106 in pregnancy, 849 PEG-IFN-α. See Interferon (IFN)-α
Parasitic infections red cell antigens and resistance to, 2340 Pel-Ebstein fever, 1607
blood loss from, 629 transient aplastic crisis and, 541 Pelger-Huët anomaly, 1350f, 1353, 1465
eosinophils and, 956–957, 957t Passenger mutations, 1348 Pellagra (niacin deficiency), 652
purpuras and, 2105, 2105f Pasteur effect, 504 Pemetrexed, megaloblastic anemia and, 605,
Paratarg-7, 1708, 1709–1710, 1734 Patch, 1680 606t
Paresthesias, 5, 632 Paternal zygosity, 852 Penetrance, 149
Paris-Trousseau syndrome, 2061 Patient blood management, 2378 Penicillins
Parkinson disease, 453, 1125 Patient-specific blood donation, 2368 for bartonellosis, 818
Paroxetine, 2079 Pattern recognition receptors drug-mediated immune injury and,
Paroxysmal cold hemoglobinuria (PCH), dendritic cells and, 307 829–830, 832
837, 839, 2348 macrophage polarization and, 1085 platelet function and, 2078
Paroxysmal nocturnal hemoglobinuria Pauciblastic leukemia. See Oligoblastic prophylactic, in sickle cell disease, 773
(PNH), 571–581 myelogenous leukemia (refractory Pentachlorophenol (PCP), 517
aplastic anemia, 520, 521 anemia with excess blasts) Pentostatin (deoxycoformycin), 325
vs. autoimmune hemolytic anemia, 837 Pautrier microabscesses, 1681 for chronic lymphocytic leukemia, 1534,
in children, 580 Pax5, 1141, 1155 1535, 1537
classification of, 576t PAX5, 1606, 1627, 1710, 1710f for hairy cell leukemia, 1553, 1557–1558,
clinical features, 573, 575, 1286, 2100, PAX5, 1508, 1626 1559t
2100f Paxillin, 251, 266 for hepatosplenic T-cell lymphoma, 1701
course and prognosis, 580–581 PBG (porphobilinogen), 889, 891f, 903 mechanism of action, 322
definition and history, 570 PBGD, 901 for mycosis fungoides, 1687
differential diagnosis, 576–578 PBGD (porphobilinogen deaminase), 701t, structure, 323f
epidemiology, 571–572 894 for Waldenström macroglobulinemia, 1794
etiology and pathogenesis, 572–573 PBG (porphobilinogen) synthase, 894, 918 Pentoxifylline
complement-mediated, 572, 572f PBPCs (peripheral blood progenitor cells), antiplatelet effects, 404
GPI-linked protein deficiency, 1871, 355–356 clinical uses, 404t
2337 PCC (prothrombin complex concentrate), dosage, 404t
molecular and genetic basis of, 572–573, 396, 2135, 2136, 2136t for heart valve hemolysis, 805
573f PCFCL (primary cutaneous follicular center for peripheral arterial disease, 2297
phenotypic mosaicism in, 573, 574–575f lymphoma), 184t for peripheral vascular disease, 405

Kaushansky_index_p2393-2506.indd 2475 9/21/15 3:22 PM